Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Fineline Cube Aug 19, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Fineline Cube Aug 19, 2026
Company Deals

ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital

Fineline Cube Jul 25, 2022

Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution,...

Company Deals

Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion

Fineline Cube Jul 25, 2022

Innovita Biological Technology Co., Ltd, a Beijing-based point-of-care testing (POCT) specialist, is set to make...

Company Drug

Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital

Fineline Cube Jul 25, 2022

Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate...

Company Deals

Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech

Fineline Cube Jul 22, 2022

Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million...

Company Deals

Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001

Fineline Cube Jul 22, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4...

Company Deals

Curatia Medical Raises Tens of Millions in Funding Co-led by Hidea Investment

Fineline Cube Jul 22, 2022

Curatia Medical Ltd, a vascular interventional therapy developer with operations in Silicon Valley, California, and...

Company Deals

Novaremed AG Licenses NRD.E1 to NeuroFront for Greater China Development

Fineline Cube Jul 22, 2022

Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd,...

Drug

Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study

Fineline Cube Jul 22, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...

Company Drug

Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC

Fineline Cube Jul 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...

Company Deals

Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang

Fineline Cube Jul 22, 2022

China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy...

Company Drug

Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye

Fineline Cube Jul 22, 2022

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity

Fineline Cube Jul 22, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Drug

Sinopep-Allsino Biopharm’s SPN0103-009 Receives NMPA Approval for Diabetes and Obesity Clinical Study

Fineline Cube Jul 22, 2022

China-based Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd announced that it has received approval from the National...

Drug

Lepu Biopharma’s Pucotenlimab Receives Conditional NMPA Approval for MSI-H/dMMR Tumors

Fineline Cube Jul 22, 2022

The National Medical Products Administration (NMPA) has granted conditional market approval to Lepu Biopharma Co.,...

Company Deals

Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base

Fineline Cube Jul 22, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue...

Company Drug

Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE

Fineline Cube Jul 22, 2022

The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’...

Company

Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics

Fineline Cube Jul 22, 2022

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in...

Company Drug

InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone

Fineline Cube Jul 22, 2022

China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade...

Company Deals

Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC

Fineline Cube Jul 21, 2022

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...

Company Deals

MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines

Fineline Cube Jul 21, 2022

MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9...

Posts pagination

1 … 690 691 692 … 710

Recent updates

  • Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China
  • Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists
  • FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19
  • Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting
  • Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Company Medical Device

Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.